You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5 Results
Guidelines and Advice
Status: Archived
ID: CED 19
Jul 2010
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide
ODB - General Benefit
    bicalutamide
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
leuprolide,
bicalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2026
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    binimetinib - For the treatment of patients with locally advanced unresectable or metastatic melanoma with a BRAF V600 mutation, based on criteria
Exceptional Access Program
    encorafenib - For the treatment of patients with locally advanced unresectable or metastatic melanoma with a BRAF V600 mutation, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
binimetinib,
encorafenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2026
Drug
Other Name(s): Velcade®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2026
Drug
Other Name(s): Treanda®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2026